title: [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
abstract: Vedolizumab, the first drug in the class of anti-integrin molecules, is newly approved for ulcerative colitis and Crohn's disease and can be prescribed in Germany since mid-2014. By a specific receptor binding a relatively gut-selective mode of action was achieved without the known side effects of the systemic immunosuppression of the anti-TNF-alpha antibodies. According to the present data the safety profile of Vedolizumab appears to be more favorable than that of the anti-TNF- alpha therapy. Vedolizumab is suitable for induction therapy in patients with ulcerative colitis and Crohn's disease, however the kinetic of response compared with the anti-TNF-alpha antibodies seems to be slower. For maintenance therapy the Vedolizumab data show a deep and sustained remission in patients initially responding to induction therapy with a lower loss of efficacy in the long-term treatment known from the anti-TNF-alpha therapy. On the basis of currently available data the efficacy of Vedolizumab in ulcerative colitis appears to be slightly better than in Crohn's disease.
authors.affiliation: Clinic for Internal Medicine I, Kiel, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Schreiber
authors.affiliation: Medizinische Klinik I, Markus-Krankenhaus Frankfurter Diakonie-Kliniken, Frankfurt/Main, Germany.
authors.forename: A U
authors.initials: AU
authors.lastname: Dignass
authors.affiliation: Gastroenterologische Gemeinschaftspraxis, Herne, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Hartmann
authors.affiliation: Evangelisches Krankenhaus Kalk, Köln, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Kruis
authors.affiliation: Zürich Center for Integrative Human Physiology (ZIHP), Zürich, Switzerland.
authors.forename: G
authors.initials: G
authors.lastname: Rogler
authors.affiliation: Charité, Berlin, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Siegmund
authors.affiliation: Universitätsklinikum Jena, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Stallmach
authors.affiliation: DCCV, Berlin, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Witte
authors.affiliation: Gastroenterologische Gemeinschaftspraxis Minden, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Bokemeyer
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy*; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; C543529:vedolizumab